FOXJ1 Inhibitors
The class of FOXJ1 inhibitors comprises a diverse array of chemical compounds that intricately modulate cellular processes and signaling pathways, leading to the inhibition of FOXJ1 functionality. One such inhibitor, CX-4945 (Silmitasertib), exemplifies this class by indirectly inhibiting FOXJ1 through targeting the CK2 signaling pathway. As a CK2 inhibitor, CX-4945 disrupts the phosphorylation events crucial for FOXJ1 activation. This disruption leads to altered transcriptional regulation, impacting FOXJ1 expression and functionality indirectly through CK2-mediated signaling modulation.
Additionally, Niclosamide indirectly inhibits FOXJ1 by affecting the Wnt/β-catenin pathway. As an inhibitor of Wnt/β-catenin signaling, Niclosamide influences downstream targets, including FOXJ1. This indirect inhibition occurs through the modulation of the Wnt pathway, leading to altered transcriptional regulation and diminished FOXJ1 functionality in cellular processes. These examples highlight the nuanced interplay between chemical inhibitors, cellular pathways, and the direct modulation of FOXJ1 activity. The precise understanding of these biochemical and cellular mechanisms provides a foundation for further exploration and refinement of targeted interventions aimed at inhibiting FOXJ1 functionality in specific cellular contexts.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
CX-4945 | 1009820-21-6 | sc-364475 sc-364475A | 2 mg 50 mg | $183.00 $800.00 | 9 | |
CX-4945 inhibits FOXJ1 indirectly by targeting the CK2 signaling pathway. As a CK2 inhibitor, it disrupts the phosphorylation events crucial for FOXJ1 activation. This disruption leads to altered transcriptional regulation, impacting FOXJ1 expression and functionality indirectly through CK2-mediated signaling modulation. | ||||||
Niclosamide | 50-65-7 | sc-250564 sc-250564A sc-250564B sc-250564C sc-250564D sc-250564E | 100 mg 1 g 10 g 100 g 1 kg 5 kg | $37.00 $77.00 $184.00 $510.00 $1224.00 $5814.00 | 8 | |
Niclosamide indirectly inhibits FOXJ1 by affecting the Wnt/β-catenin pathway. As an inhibitor of Wnt/β-catenin signaling, it influences downstream targets, including FOXJ1. This indirect inhibition occurs through the modulation of the Wnt pathway, leading to altered transcriptional regulation and diminished FOXJ1 functionality in cellular processes. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $226.00 $846.00 | 1 | |
JQ1 inhibits FOXJ1 indirectly by targeting the BET family of proteins. As a BET bromodomain inhibitor, JQ1 modulates gene expression and downstream effectors, including FOXJ1. This indirect inhibition occurs through epigenetic modifications, influencing the stability and activity of FOXJ1 in cellular processes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 inhibits FOXJ1 indirectly by targeting the PI3K/AKT signaling pathway. As a PI3K inhibitor, it modulates downstream effectors, including FOXJ1. This indirect inhibition occurs through the disruption of the PI3K/AKT pathway, leading to altered transcriptional regulation and diminished FOXJ1 functionality in cellular processes. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Brefeldin A inhibits FOXJ1 indirectly by disrupting the Golgi apparatus and vesicular transport. By interfering with intracellular trafficking, it affects the proper localization and function of FOXJ1. This indirect inhibition occurs through the modulation of vesicular transport, leading to altered cellular processes and diminished FOXJ1 functionality. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 inhibits FOXJ1 indirectly by targeting the p38 MAPK signaling pathway. As a p38 MAPK inhibitor, it modulates downstream effectors, including FOXJ1. This indirect inhibition occurs through the disruption of the p38 MAPK pathway, leading to altered transcriptional regulation and diminished FOXJ1 functionality in cellular processes. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits FOXJ1 indirectly by targeting the mTOR signaling pathway. By binding to FKBP12 and inhibiting mTORC1, Rapamycin modulates downstream effectors, including FOXJ1. This indirect inhibition occurs through the disruption of mTOR signaling, leading to altered transcriptional regulation and diminished FOXJ1 functionality in cellular processes. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib inhibits FOXJ1 indirectly by targeting the Src family of kinases. As a kinase inhibitor, it influences downstream signaling events, including FOXJ1 regulation. This indirect inhibition occurs through the modulation of Src family kinases, leading to altered transcriptional regulation and diminished FOXJ1 functionality in cellular processes. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $70.00 $198.00 | 18 | |
SB216763 inhibits FOXJ1 indirectly by targeting the GSK-3β signaling pathway. As a GSK-3β inhibitor, it modulates downstream substrates, including FOXJ1. This indirect inhibition occurs through the disruption of GSK-3β-mediated phosphorylation events, leading to altered transcriptional regulation and diminished FOXJ1 functionality in cellular processes. | ||||||
Flavopiridol Hydrochloride | 131740-09-5 | sc-207687 | 10 mg | $311.00 | ||
Flavopiridol inhibits FOXJ1 indirectly by targeting cyclin-dependent kinases (CDKs). As a CDK inhibitor, it modulates cell cycle progression and downstream signaling, including FOXJ1 regulation. This indirect inhibition occurs through the disruption of CDK-mediated phosphorylation events, leading to altered transcriptional regulation and diminished FOXJ1 functionality in cellular processes. | ||||||